Formulation and characterization of blonanserin tablet using liquisolid techniques

Blonanserin use to treat Schizophrenia and other bipolar disorder. It is BCS II drug having low solubility. The affinity of Blonanserin for D2 receptors is 20 and 94 fold higher than that of haloperidol and risperidone, respectively. Blonanserin has low affinity for 5-HT2C, adrenergic α1, histamine H1, and muscarinic M1 receptors which decrease certain adverse effects such as orthostatic hypotension, over sedation, weight gain, metabolic abnormalities, and peripheral anticholin ergic side effects. In this present research work blonanserin tablet was prepared using liquisolid techniques to increase solubility and bio availability of drug. Avicel ph 200 and Cab o sil was taken as carrier and coating material respectively. Blonanserin is more soluble in PEG 600 than other non volatile solvent. Optimization was done on the basis of 32 full factorial designs by taking different ratio of carrier and coating material to various drug concentrations in solvent. By the result it was observed that dissolution rate of blonanserin was significantly increase using this formulation.